Company Analysis
Sign in

enVVeno Medical Corporation (NVNO)

Nasdaq: NVNO · Surgical & Medical Instruments & Apparatus · Irvine, CA · filing with the SEC since 2015
Full chart Alerts Compare
Grade3.6
◀ Past 1.8● Present 4.4▶ Future 4.2
3 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

The grade of enVVeno Medical Corporation

Nine metrics read from its own filings, by tense
Headline grade
3.6/10
◀ Past1.830% of the headline
● Present4.440% of the headline
▶ Future4.230% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 6 read as filed from the record and 3 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

1.8/1030% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed
1.9/10

Has it survived what it has been through?

7 warning events since 2017; the latest 2025-10-10.

weight 33% of this tense · 19th percentile among 121 sector filers · read for itself

From the record

enVVeno Medical Corporation's filings since 2017 show 7 warning events of 3 kinds: a notice about its exchange listing (8-K item 3.01, 5 times, the latest 2025-10-10); an auditor change (8-K item 4.01, the latest 2025-04-21); a late-report notice (Form NT 10-K or NT 10-Q, the latest 2020-11-17) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed
0.8/10

What has it actually done, year after year?

-72.8% a year over 3 filed years; profitable in 0 of 3.

weight 45% of this tense · 8th percentile among 105 sector filers · read for its customers

From the record

enVVeno Medical Corporation's 3 filed years say what it did: revenue went from $422 thousand in fiscal 2017 to $31 thousand in fiscal 2019, down 72.8% a year; it rose in 0 of 2 years; the deepest fall was 93% from fiscal 2017 to fiscal 2019; net income was positive in 0 of 3 of those years (its annual reports).

What it rests on

  • revenue growth over the filed span-72.8%bottom 1% of its family
  • the share of years revenue rosebottom 2% of its family
  • the share of filed years with a profitbottom 23% of its family
  • the deepest fall from a revenue peak92.6%bottom 7% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate
3.7/10

How has it treated the people who own it?

SI estimate 3.7/10, confidence 35 of 100 (one part).

weight 22% of this tense · 37th percentile among 120 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, the share count over the years, which ranks in the bottom 37% of 120 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read
Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned
one part: the share count over the years, the one part on file, ranked among 120 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: enVVeno Medical Corporation's shareholder treatment is put at 3.7 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 37% of 120 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

4.4/1040% of the headline grade · 3 of 3 filed

Financial health

as filed
5.8/10

Is it financially healthy right now?

ROE -72%: lost 72¢ per shareholder dollar. Leverage 8%: owes 8¢ per asset dollar.

weight 45% of this tense · 57th percentile among 120 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, enVVeno Medical Corporation lost about 72 cents for every dollar of shareholders' money. Leverage: it owed about 8 cents per dollar of assets, and net share issuance: its share count grew 20.2% over the year (the filed statements).

What it rests on

  • what it owes per dollar of assetstop 4% of its family
  • return on equitybottom 36% of its family
  • the share count against the year beforebottom 40% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed
0.1/10

How strong is its position in its industry?

bottom 1% of 109 in its family; net margin -24406.7%.

weight 33% of this tense · 1st percentile among 109 sector filers · read for its customers

From the record

enVVeno Medical Corporation's standing among 109 graded names in its industry family: revenue of $31 thousand in fiscal 2019 ranks in the bottom 1% by size; a net margin of -24406.7% ranks in the bottom 1%; revenue growth of -72.8% a year over the last 2 filed years ranks in the bottom 1% (its annual reports).

What it rests on

  • revenue against the family$31,243bottom 1% of its family
  • net margin-24406.7%bottom 1% of its family
  • three-year revenue growth-72.8%bottom 1% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

as filed
8.2/10

What are the people in charge doing?

top 19% of 91 in its family for leadership; chief executive since 2018.

weight 22% of this tense · 81st percentile among 91 sector filers · read for its shareholders

From the record

enVVeno Medical Corporation's leadership, from its insiders' filings and its current reports: the chief executive on the record is Berman, Robert Andrew (Chief Executive Officer, as filed), filing under that title since 2018-05-30, 8.5 years (top 30% of its family); the 7 officers and directors filing in the last fifteen months have been on the record a median of 8 years (top 19%); 1 officer or director change was reported on Form 8-K since 2023-11-13, against the 7 people in charge now (top 6%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

What it rests on

  • officer and director changes on Form 8-K, against the people in charge1 in three years among 7 peopletop 6% of its family
  • the median years the people in charge have filed8.0 yearstop 19% of its family
  • the chief executive's years on the record8.5 yearstop 30% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

▶ Future

What are they set up to do next?

4.2/1030% of the headline grade · 1 of 3 filed, 2 estimated

Room to expand

SI estimate
5.0/10

How much room does it have to grow?

SI estimate 5.0/10, confidence 35 of 100 (one part).

weight 45% of this tense · 50th percentile among 120 sector filers · read for itself

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, cash less debt against assets, which ranks in the bottom 50% of 120 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue.
What the record cannot read
The record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue.
How it was reasoned
one part: cash less debt against assets, the one part on file, ranked among 120 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: enVVeno Medical Corporation's room to expand is put at 5.0 of 10 with a confidence of 35 of 100, because read from one part only, cash less debt against assets, which ranks in the bottom 50% of 120 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue. A filing that carries the missing parts replaces this estimate with the filed reading.

Growth drivers

as filed
2.5/10

What could actually drive growth from here?

bottom 26% of 105 in its family for growth drivers.

weight 33% of this tense · 26th percentile among 105 sector filers · read for its customers

From the record

enVVeno Medical Corporation's growth drivers, from the filed years to fiscal 2019: revenue grew -72.8% a year over the last three filed years against -72.8% over all 3, speeding up (top 43% of its family); the newest year grew -83.3% (bottom 4%); research spending grew 0.2% a year (bottom 33%); capital spending grew -64.8% a year (bottom 8%) (its annual reports). enVVeno Medical Corporation tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

  • three-year growth against the whole span+0.0 points a yeartop 43% of its family
  • the newest year's revenue growth-83.3%bottom 4% of its family
  • three-year growth of research spending0.2%bottom 33% of its family
  • three-year growth of capital spending-64.8%bottom 8% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

SI estimate
5.1/10

Did its newest year beat what its own record pointed to?

SI estimate 5.1/10, confidence 20 of 100 (family median).

weight 22% of this tense · 50th percentile among 88 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 88 members with one.
What the record cannot read
The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
How it was reasoned
family median, 88 readings behind it.
Confidence
20 of 100
What would change it
Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: enVVeno Medical Corporation's expectations vs reality is put at 5.1 of 10 with a confidence of 20 of 100, because the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 88 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton NVNO · research, not advice